Lyell Immunopharma (LYEL) Operating Expenses (2020 - 2026)

Lyell Immunopharma's Operating Expenses history runs 7 years deep, the most recent figure standing at $44.3 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 22.85% year-over-year to $44.3 million; the TTM figure through Mar 2026 stood at $256.3 million (down 28.92% YoY), while the FY2025 annual figure was $269.4 million, down 24.91% from the prior year.
• Operating Expenses came in at $44.3 million for Q1 2026 at Lyell Immunopharma, down from $127.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $201.2 million in Q4 2024 to a low of $37.3 million in Q3 2025.
• A 5-year average of $70.1 million and a median of $59.5 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses surged 237.96% in 2024 and slumped 36.54% in 2025, its largest moves.
• Lyell Immunopharma's Operating Expenses stood at $63.2 million in 2022, then retreated by 5.78% to $59.5 million in 2023, then soared by 237.96% to $201.2 million in 2024, then plunged by 36.54% to $127.6 million in 2025, then tumbled by 65.32% to $44.3 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $44.3 million, $127.6 million, and $37.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison